Floatz logo

Lornoxicam

Neuropathic Pain

Konya Beyhekim Training and Research HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

55 Active assets in the Neuropathic Pain cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Ataturk University
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Margaux M. Salas, PhD
Phase 4BBB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Medipol University
Phase 4BBB
Capsaicin
University Hospital, Clermont-Ferrand
Phase 4BBB
Pregabalin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4BBB

View all 50 →

Same molecule, other indications

Lornoxicam is also rated in:

neoplasmDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
57 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →